Japanese Pricing Rules Don’t Fully Capture Value of New Modalities, “No” to CEA Expansion: Janssen Exec

Christoph Glaetzer, Chief Global Value and Access Officer, Global Commercial Strategy Organization, Janssen Pharmaceutical Companies of Johnson & Johnson While Japan has a well-structured pharmaceutical pricing system, it has been unable to fully recognize the value of new therapeutic modalities,...read more